Reneuron Share Discussion Threads

[small crow] 21/1/2020 12:25

That's more like it.

[dickbush] 17/1/2020 13:44

Thanks for the article, Lauders. It seems to have generated some enthusiasm today, presumably on the thought that it might be acquired. Why no one has stepped up to buy the 33% from Ex-Woodford funds-on the cheap-suggests any acquirers are in Show Me mode. Let's hope that the updates from the RP trials this year give us (and them) good news.

[napoleon 14th] 17/1/2020 12:49

They just have!

Bought a few more.

[bonzo] 17/1/2020 12:21

Just topped up again, these have to start moving up at some point!

[lauders] 17/1/2020 10:27

RENE mentioned in this piece:

Whether it comes to be is another matter completely, but interesting RENE are included.

These scenarios could eventually play out for a minnow such as ReNeuron, a £44m gene therapy specialist which we have previously described as having “highly promising technologies tempered by uncertainties linked to the funding imperative”.

The company is developing stem-cell technologies for use in therapies to combat chronic stroke disability and certain types of retinal degeneration. Clinical results have been positive, but the company’s management is attempting to shorten the overall time to market approval, thereby easing the capital imperative to a degree.

ReNeuron had net cash of £20.3m at the time of its September interim result, but it burnt through £7.48m in net cash during FY2019 with R&D expenditure up 22 per cent to £9.23m. We do not envisage any let-up in the capital demands given the clinical trials in prospect, but matters have been helped by the payment of half of the £12m upfront fee from Fosun Pharma for the potential commercial exploitation of the company’s therapies in China.

The agreement with Fosun, signed last April, could generate success-based milestone payments of £80m and double-digit royalties on sales, but it is hard to imagine that a $14.5bn (£11.2bn) group like Fosun wouldn’t be interested in incorporating ReNeuron’s intellectual property within its balance sheet further down the track.

Asia is currently the fastest growing region for pharmaceutical investment in the world – with M&A playing an increasingly prominent role. Gene-based therapies represent the new frontier in medical research, underpinning a new tailored approach to clinical applications, aided by the accumulation of massive new datasets across population groups. If ReNeuron’s technologies are eventually deemed efficacious by regulators, then Fosun may have to act quickly, because these technologies would not have gone unnoticed closer to home.

[lauders] 07/1/2020 11:17

I did wonder about that martinfrench, but I thought only UK and US based patients would be considered. Could be a bit challenging in Thailand. Will certainly watch and perhaps send a message to the company if more and more progress is evident.

[martinfrench] 07/1/2020 11:11

depending on his financial situation i would volunteer for trials

[lauders] 06/1/2020 01:45

Yesterday I spent most of the day with one of my wife's friends and her second eldest son (24 years old). They are Thai and I learnt that he has retinitis pigmentosa (RP). It was an eye-opener to hear directly from him about his daily challenges. He doesn't like to go to crowded places as he can bump into people as his tunnel vision doesn't allow him to see around him clearly, he has nearly been hit by two cars trying to cross the road, when people try to shake hands with him they look at him strangely when he doesn't seem to lift his hand and reciprocate etc... These are just some of the obvious things that struck me as frustrating for him and things that we normal folk would not even consider/understand.

He seemed to know about Reneuron and I showed him the website on my mobile so he knows there is some hope, but at what price and when? These are the critical things in his mind as his eyesight diminishes. I now have even more reason to see RENE's work pay-off and hope that I will be able to see him benefit from it all, before it is too late for him. Fingers and everything else crossed!

[diversification] 31/12/2019 10:26

Looking very strong after a strong period of consolidation we should see further commercial deals in short order as per recent interview.

[dickbush] 31/12/2019 10:02

Three cheers for the last day of the year's trading. Break-out above 50 day moving average which is also bottoming out.

[costax1654x] 31/12/2019 09:20

Idp looks lovely as well!My top picks for 2020

[lauders] 26/12/2019 08:33

Very interesting that Michael Schumacher is undergoing stem cell surgery to try and help him. Hope the outcome is very positive for him and his legion of fans. Let 2020 be a great year for him in the way of recovery and hence an easier one for his family.

[bg23] 19/12/2019 15:04

new Edison report out today.

hxxps://www.edisongroup.com/publication/a-transformational-year-2/25879

from the little I know and understand it reads well although I think there are questions it doesn't touch such as the likelihood of deals similar to the Fosun deal.
I'd also have appreciated an indication of dates for updates to the business.

still, happy to hold and hope Mr Woodfords overseers can arrange either a painless exit or indeed decide to retain based on recent results.

[brad_k] 18/12/2019 15:06

According to Reneuron website Link Funds are still at 16.42%
Todays RNS is just the other side of Fridays notification from Schroder that they have assumed management of the former Woodford PCT fund.
What is clear however is the level of interest in RENE shares once investors are persuaded that these shares have found a home.

[investordave] 18/12/2019 14:58

I was about to ask the same thing. I don't see how Link can have sold yet.

[hashertu] 18/12/2019 14:43

cyberbub. Why do you say that?

[cyberbub] 18/12/2019 13:28

Link Fund shares now all sold...

[hashertu] 18/12/2019 10:57

Abstract from Link Fund Solutions, investor note.
My interpretation is that sale of assets (RENE) can occur after January if an acceptable price cannot be obtained.

"It is anticipated that the first capital distribution will be paid to you and all other investors by the end of January 2020. The size of this first capital distribution will depend upon how quickly the value of the Fund’s assets can be realised. We will write to you before this payment is made to provide further details.
At the point at which the winding up of the Fund begins, any remaining less liquid assets of the Fund (including the unlisted assets) will continue to be sold over time in an orderly manner to seek to limit the loss of value which would be the key risk if they were sold on a forced or “fire sale” basis.
It is not currently possible to predict when the orderly sale of these remaining assets will be fully complete and when the remaining capital distributions will be paid to you and the other investors."

[masingi] 17/12/2019 09:46

Actually, a forced sell at low price by a big fund is good for small investors that want to buy in. It's usually the other way around!

[diversification] 16/12/2019 19:48

Let's remember the cash position though, regardless of who owns the fund. This has fundamental value, and as investors you don't sell without a CONSIDERED evaluation of the bottom line.

[brad_k] 16/12/2019 18:28

Yes Woodford PCT has now been renamed Schroder UK Public Private Trust and as of Dec 16th the former PCT assets are now being managed by Schroder. Hopefully if they decide to redo their holding of RENE they will find one or more Its to take significant holdings, a drip feed of sells into the market would not help the share price
The Link Funds 16.42% holding however has to be liquidated by the end of January and it does not appear that they have shifted any since Oct 17th.

[dickbush] 16/12/2019 17:57

Link still has 16.42%.

Is the announcement of Schroder having 16.58% a transfer or has Schroder become the manager of all of the fund that has this shareholding. Any announcements on other sites of Schroder having Woodford holdings as of Friday? I don't know what else Woodford holds in that fund.